• Dedicated to improving human health by facilitating key medical breakthroughs and their applications worldwide

  • ABOUT

    Ming Capital is a global healthcare venture capital firm founded in Shenzhen, China in April 2015.

    Strategy

    • Support global medical breakthroughs (especially in innovative medicine, biotech, medical device).
    • Facilitate worldwide resources combination of medical innovations, entrepreneurship, management, commercial markets, and capital markets through onshore-offshore parallel funds and parallel investments.

    Strategic Goals

       Support entrepreneurs.  Prosper investors. Reward partners.  Enhance health.


    Values

    Cellective intelligence and wisdom of integrity for value creation.

     

  • MANAGEMENT TEAM

    An international and professional team with veteran management

    Jack (Bing) Yang

    Founding Partner

    • Over 25 year experiences in (VC/PE) investment and M&A investment banking acquired with New Hope Industry Funds, Rothschild Investment Banking, China Leasing, etc. in Beijing, Tokyo, London, Hong Kong, and Shenzhen
    • BA Economics, Peking University; Msc Finance, London Business School

    Lisa (Li) Feng

    Partner

    • Over 20 year experiences in pharmaceutical industry with Brightech International, Theravance, Anacor Pharmaceuticals, Kosan Biosciences
    • B.S., Chemistry, Peking University; M.S., Biochemistry and Molecular Biology, UNIVERSITY OF IOWA

    Samuel (SY) Cheung

    Partner

    • Over 30 years of founding startups experience and business management experience acquired while assuming senior management / board director roles with HK listed companies and HK and PRC private companies.

    Xin Wan

    Partner

    • Over 30 years of founding startups experience  in various industries such as high technology industry, chain business, bulk commodity, new energy resources, studios and animation, creative park,  real estate, venture capital, etc.
    • Master of Systems Engineering, Shanghai Jiao Tong University

    Qinghao Fu

    Managing Director

    • Over 15 years of experience in healthcare and life science industries with functions ranging from neuroscience research, marketing research and investing
    • B.S., Biology, Peking University; M.S., Neuroscience, Boston University, MBA, Washington University in St. Louis

    Ofer Hornick (MD)

    Senior Consultant Regulatory Affairs

    • Over 20 year experiences in R&D, regulatory affairs (FDA, CE, etc.) and founding startups in the fields of medical devices and digital health
    • MD,  Sackler Faculty of Medicine, Tel-Aviv University
  • PORTFOLIO

    Support innovative companies developing and using world leading technology to improve human life

    BeBetter Med.

    BeBetter, a company engaged in small molecule cancer drug discovery and development. It has established pipelines covering lymphoma, breast cancer, lung cancer, ovarian cancer etc.

    BEBT-908 is a 1.1 dual-target new drug for recurrent or refractory lymphoma.

    Binhui Biopharmaceutical Co.

    Binhui Biopharmaceutical Co., Ltd. is a leading independent company of oncolytic virus immunotherapy in China, devoting to research and development in OV for more than ten years.

    CareTaker Medical

    Caretaker Medical makes the world’s most innovative clinical grade monitor that measures continuous non-invasive blood pressure (“cNIBP”) beat by beat, heart rate and other physiological parameters of the patient.

    Eureka Biotechnology

    Eureka Biotechnology provides advanced solution for R&D of cancer immunotherapy including automatic cell therapy manufacturing equipment and viral vector production platform.

    Genevector therapeutics

    Genevector therapeutics is dedicated to the development of novel AAV gene therapy drugs. The company focuse on gene therapy for macular degeneration and other major diseases such as hereditary diseases, cardiovascular etc.

    Gordian Surgical

    Gordian Surgical has developed an integrated port closure system offering surgeons a simple, secure and safe solution to open and suture close the abdominal wall during laparoscopic procedures.

    Human Xtensions

    Human Extensions develops unmediated smart surgical systems that combine the advantages of robotics with the benefits of handheld tools and ergonomic bed mounts.

    Miracor Medical

    Miracor Medical SA has developed a technology platform designed to improve clinical outcome of patients with impaired cardiac function.

    Cucop

    Cucup uses its proprietary and leading DPI (deep packet inspection) technology to help owners of local internet networks in China to monitor and manage all network access points and generate revenue through big-data based business models such as precision advertising, etc.

    EDADOC

    EDADOC is the largest high-speed PCB design center in China and the world, and specializes in providing high-speed turn-key PCB services (PCB design, fabrication, PCBA, and supply chain services) to more than 5,000 clients globally.

  • EXITS

    With access to our partners’ experience and our excellent industry background, we spare no efforts in helping our entrepreneurs and their companies succeed!

    Keystone Heart

    Keystone Heart Ltd. is a medical device company developing and manufacturing cerebral embolic protection (CEP) device to reduce the risk of stroke.

    Supoin

    Supoin is an leading Chinese company engaged in R&D, manufacturing and sales of automatic identification products and IoT mobile products, and providing enterprise mobile application services.

    Cucop

    Cucop uses its proprietary and leading DPI (deep packet inspection) technology to help owners of local internet networks in China to monitor and manage all network access points and generate revenue through big-data based business models such as precision advertising,etc .

  • NEWS

    Yangtze River Pharmaceutical strategic investment in Binhui bio

    September 29th,2021

    Yangzi River Pharmaceutical Group reached a strategic cooperation with Wuhan Binhui Biotechnology Co., Ltd., an independent R & D enterprise of oncolytic virus drugs, and announced that the two sides would strengthen cooperation in the field of biomedicine.

    Caretaker Medical receives new investment from Philips and others to enhance the Caretaker wireless Vital Signs patient monitoring platform

    Caretaker Medical, a leader in clinical-grade wireless patient monitoring and maker of the Caretaker® wearable patient monitor that utilizes a simple Finger Cuff to remotely measure “Beat by Beat” Continuous Blood Pressure and multiple vital signs has announced the completion of a Series B funding round from new investors Philips and Ming Capital, with participation from existing investors including IrishAngels, Felton Group LLC, and others.

    Miracor Medical’s PiCSO® System Receives CE Mark

    Miracor Medical SA (Miracor Medical) has announced the award of the CE Mark for its latest generation of PiCSO Impulse Catheter and PiCSO Impulse Console, which is indicated for the treatment of anterior STEMI patients.

    Miracor Medical Granted FDA Breakthrough Device Designation for the PiCSO Impulse System on August 22nd, 2019

    Miracor Medical SA (Miracor Medical) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its PiCSO® Impulse System for treatment of STEMI patients.

    In July of this year, Miracor announced the start of its European randomized study, PiCSO-AMI-I, to further evaluate the benefits of PiCSO therapy as compared with conventional PCI for the treatment of anterior STEMI patients.

    Miracor Medical closes final tranche of Series-D, bringing the round to €30M on September 4th, 2018

    The Series D capital will be used to further develop and commercialize the PiCSO® Impulse System. The Series-D round was led by Ming Capital (Shenzhen, China) and co-led by a strategic investor. Participating new investors include Belgian alternative investment fund Quest for Growth, and participating existing investors include Ming Capital, SFPI and Meusinvest. The technical and clinical research programs of Miracor are also supported by a financing program of the DGO6 (Walloon Government).

    Miracor Medical Raises € 25M on January 4th, 2018

    Miracor Medical today announced the closing of € 25m as part of a Series D financing round. The new capital will be used to further develop and commercialize the PiCSO® Impulse System. The round was led by Ming Capital (Shenzhen, China) and co-led by a strategic investor.

    视微影像完成超3亿元C轮融资,眼科器械国产替代拐点已至

    动脉网独家获悉,视微影像有限公司(后文简称“视微”)目前宣布完成超3亿元人民币C轮融资。本轮融资由国寿股权与前海方舟领投,辰德资本、深创投、中金汇融、华创毅达、临港蓝湾、小明投资跟投,原机构股东继续加注,硬科技领域知名FA机构云岫资本担任独家财务顾问。

  • CONTACT

    info@mingcapital.cn

    1610, 6009 Yitian Road Shenzhen, China (518038)

    +86 (755) 2399 8758